Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.49 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407327 | 0.85 | EGLN1 (0.51) | EGLN1FTOKDM5BKDM2ABBOX1 | |
| SCHEMBL3407563 | 0.82 | EGLN1 (0.56) | EGLN1FTOKDM5BKDM2ABBOX1 | |
| SCHEMBL3404446 | 0.82 | EGLN1 (0.56) | EGLN1FTOKDM5BKDM2ATHRA | |
| SCHEMBL3401638 | 0.82 | EGLN1 (0.57) | EGLN1FTOKDM5BKDM2ATHRA | |
| SCHEMBL3404507 | 0.81 | EGLN1 (0.49) | EGLN1FTOKDM5BKDM2ABBOX1 | |
| SCHEMBL3404702 | 0.80 | EGLN1 (0.57) | EGLN1FTOKDM5BKDM2ABBOX1 | |
| SCHEMBL3404542 | 0.80 | EGLN1 (0.49) | EGLN1FTOKDM5BKDM2ABBOX1 | |
| SCHEMBL3401816 | 0.80 | EGLN1 (0.57) | EGLN1FTOKDM5BKDM2ABBOX1 | |
| SCHEMBL3407319 | 0.78 | EGLN1 (0.45) | EGLN1FTOKDM5BKDM2ATHRA | |
| SCHEMBL3403372 | 0.78 | EGLN1 (0.54) | EGLN1FTOKDM5BKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387200-B2 | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity | FIBROGEN, INC. (US) | 2016-07-12 | — | — | US | claimed |
| US-20150209336-A1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN, INC. | 2015-07-30 | — | — | US | claimed |
| US-8952160-B2 | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity | FIBROGEN, INC. (US) | 2015-02-10 | — | — | US | claimed |
| EP-2252619-B1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN INC (US) | 2013-10-09 | — | — | EP | claimed |
| US-20100330199-A1 | ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN, INC. | 2010-12-30 | — | — | US | claimed |
| EP-2252619-A1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | Fibrogen, Inc. (US) | 2010-11-24 | — | — | EP | claimed |
| WO-2009089547-A1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN, INC. (US) | 2009-07-16 | — | — | WO | claimed |
| US-9387200-B2 | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity | FIBROGEN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150209336-A1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN, INC. | 2015-07-30 | — | — | US | disclosed |
| US-8952160-B2 | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity | FIBROGEN, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2252619-B1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN INC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20100330199-A1 | ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| EP-2252619-A1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | Fibrogen, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009089547-A1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330199-A1 | ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | HIF1A, HIF1AN, EGLN3 | EGLN1 5/4885FTO 2710/4885KDM5B 1485/4885 |
| US-20150209336-A1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | HIF1A, HIF1AN, EGLN3 | EGLN1 5/4885FTO 2754/4885KDM5B 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.